RNA

Total RNA was prepared from cell line WM3682. WM3682 is a metastatic human melanoma cell line. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3682 cells match with WM3702 and WM3758. These cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3682. WM3682 is a metastatic human melanoma cell line. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3682 cells match with WM3702 and WM3758. These cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3682. WM3682 is a metastatic human melanoma cell line. This cell line was established from a lymph node metastasis site of a patient. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3682 cells match with WM3702 and WM3758. These cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3702. WM3702 is a metastatic human melanoma cell line that displays pigmented, thin elongated morphology in culture. This cell line was established from a right upper flank of back in a 58-year-old male with necrotic fungating melanoma. The subject displayed metastatic melanoma forming multiple subcutaneous nodules with overlying skin ulcerations. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3702 cells match with WM3758 and WM3682. These cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3702. WM3702 is a metastatic human melanoma cell line that displays pigmented, thin elongated morphology in culture. This cell line was established from a right upper flank of back in a 58-year-old male with necrotic fungating melanoma. The subject displayed metastatic melanoma forming multiple subcutaneous nodules with overlying skin ulcerations. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3702 cells match with WM3758 and WM3682. These cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3702. WM3702 is a metastatic human melanoma cell line that displays pigmented, thin elongated morphology in culture. This cell line was established from a right upper flank of back in a 58-year-old male with necrotic fungating melanoma. The subject displayed metastatic melanoma forming multiple subcutaneous nodules with overlying skin ulcerations. This cell line contains a Q61L mutation at position 61 in the N-RAS gene. The Q61L mutation results in an amino acid substitution at position 61 in NRAS, from a glutamine (Q) to a leucine (L). WM3702 cells match with WM3758 and WM3682. These cells produce xenograft tumors when injected into immunocompromised mice.

Total RNA was prepared from cell line WM3704. WM3704 is a metastatic human melanoma cell line that displays a mesenchymal morphology. This cell line was established from a lymph node metastasis site of a patient. This cell line features the specific V600E (Val600Glu) mutation at codon 600 in the BRAF gene. This mutation causes constitutively active kinase activity and activation of MEK and ERK signaling pathway. This cell line also expresses mutated PTEN gene and R24H mutation at position 24 in the CDK4 gene. The R24H mutation results in an amino acid substitution at codon 24 in CDK4, from an arginine (R) to histidine (H). This mutation is an activating mutation, as it results in growth advantages by preventing p16 binding, while maintaining the ability of CDK4 to form a functional kinase with cyclin D. WM3704 cells produce xenograft tumors when injected into immunocompromised mice.